Richard Schilsky to Drug Design
This is a "connection" page, showing publications Richard Schilsky has written about Drug Design.
Connection Strength
0.998
-
Commentary: tackling the challenges of developing targeted therapies for cancer. Oncologist. 2010; 15(5):484-7.
Score: 0.348
-
Target practice: oncology drug development in the era of genomic medicine. Clin Trials. 2007; 4(2):163-6; discussion 173-7.
Score: 0.283
-
Personalized medicine in oncology: the future is now. Nat Rev Drug Discov. 2010 05; 9(5):363-6.
Score: 0.089
-
The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). Clin Cancer Res. 2008 Sep 15; 14(18):5685-91.
Score: 0.080
-
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res. 2004 Jun 01; 10(11):3881-4.
Score: 0.059
-
Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res. 2004 Jun 01; 10(11):3908-18.
Score: 0.059
-
Are targeted therapies really targeted? Clin Adv Hematol Oncol. 2003 Dec; 1(12):722-3.
Score: 0.057
-
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
Score: 0.023